BioCryst Pharmaceuticals
BCRX
#5073
Rank
โ‚น143.56 B
Marketcap
โ‚น681.86
Share price
-3.07%
Change (1 day)
2.70%
Change (1 year)

BioCryst Pharmaceuticals (BCRX) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : โ‚น74.95 Billion

According to BioCryst Pharmaceuticals 's latest financial reports the company's total liabilities are โ‚น74.95 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BioCryst Pharmaceuticals - Total liabilities on balance sheet (from 2001 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31โ‚น82.90 B2.4%
2023-12-31โ‚น80.95 B15.84%
2022-12-31โ‚น69.89 B35.08%
2021-12-31โ‚น51.73 B99.86%
2020-12-31โ‚น25.88 B164.92%
2019-12-31โ‚น9.77 B43.18%
2018-12-31โ‚น6.82 B13.12%
2017-12-31โ‚น6.03 B0.58%
2016-12-31โ‚น5.99 B20.94%
2015-12-31โ‚น4.95 B27.79%
2014-12-31โ‚น3.88 B25.67%
2013-12-31โ‚น3.08 B-2.57%
2012-12-31โ‚น3.16 B-11.1%
2011-12-31โ‚น3.56 B81.07%
2010-12-31โ‚น1.96 B-24.11%
2009-12-31โ‚น2.59 B41.09%
2008-12-31โ‚น1.83 B-39.77%
2007-12-31โ‚น3.05 B45.67%
2006-12-31โ‚น2.09 B14.15%
2005-12-31โ‚น1.83 B1252.82%
2004-12-31โ‚น0.13 B80.86%
2003-12-31โ‚น75.05 M33.54%
2002-12-31โ‚น56.2 M-48.97%
2001-12-31โ‚น0.11 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Repligen
RGEN
โ‚น75.51 B 0.76%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
โ‚น195.24 B 160.49%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
โ‚น0.11 B-99.84%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
โ‚น120.07 B 60.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
โ‚น3.330 T 4,344.02%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
โ‚น4.49 B-94.00%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
โ‚น5.505 T 7,245.49%๐Ÿ‡ฌ๐Ÿ‡ง UK
Emergent BioSolutions
EBS
โ‚น78.92 B 5.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
โ‚น1.19 B-98.40%๐Ÿ‡บ๐Ÿ‡ธ USA